AI-generated analysis. Always verify with the original filing.
Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics via a reverse triangular merger, issuing 10,602.3880 shares of Series B Non-Voting Convertible Preferred Stock (each convertible into 1,000 common shares) to Faeth equityholders. Concurrently, Sensei entered a $200M PIPE financing for 14,440.395 Series B Preferred shares at ~$13,850/share, expected to close February 20, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
above. The Certificate of Designation provides for the creation of the Company’s Series B Preferred Stock. Holders of Series B Preferred Stock are entitled to r
Completion of Acquisition or Disposition of Assets. On February 17, 2026, the Company completed its acquisition of the Faeth Entities. The information contained
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment o
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 17, 2026, the Company filed with the Secretary of State of the State of De
of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, shall not be deemed to be incorporated by refere
(b) is not included in this Current Report on Form 8-K. The Company intends to include such pro forma financial information by amendment to this Current Report
Anand Parikh
Effective: February 17, 2026
Per Merger Agreement
Acquisition / Disposition
Material Agreement